Avaliação do potencial antitumoral dos complexos de ofloxacino com ciclodextrinas em células de câncer de mama MCF-7
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora - Campus Avançado de Governador Valadares
DOI
Abstract
Breast cancer is a disease caused by breast cell proliferation disorder. This process produces
abnormal cells, which multiply in a disorderly way, which leads to the formation of tumors.
Breast cancer is a heterogeneous disease with different clinical and morphological
manifestations associated with distinct genetic characteristics, therefore requiring different
therapeutic approaches. Several advances have emerged over the years with regard to the
oncological treatment of breast tumors, but the treatment depends on the stage of the disease
and the type of tumor, and may include surgery, radiotherapy, chemotherapy, hormone therapy
and targeted therapy . When this neoplasia is diagnosed in its initial phase, the treatment has a
greater curative potential. In the case of tumor metastasis, the treatment aims to prolong and
improve the patient's quality of life. Ofloxacin (OFLOX) is a fluoroquinolone with a broad
spectrum bactericidal effect that demonstrates cytotoxic activity for tumor cells. Studies show
that the association of drugs with cyclodextrins can favor the biological activity of some
substances. Therefore, the aim of this work was to evaluate the antitumor potential of OFLOX
nanostructured compositions after inclusion in β-cyclodextrin (βCD) and hydroxypropyl-β-
cyclodextrin (HPβCD) in MCF-7 breast cancer cells. To evaluate the in vitro antitumor
potential, the viability of MCF-7 cells was determined by the MTT colorimetric method for 48
and 72 hours, after treatment with inclusion complexes (IC's) at concentrations of 300 μM, 100
μM and 50 μM. For the evaluation of apoptosis and necrosis, the Annexin V apoptosis detection
kit was used by flow cytometry and the cells treated with IC's at concentrations of 300 μM. The
results obtained demonstrate that the HPβCD/OFLOX complex was able to reduce the cell
viability of MCF-7 to values below 70% at concentrations of 100 μM and 300 μM in 72 hours
of treatment. It was observed that treatment at 300 μM of HPβCD/OFLOX promoted apoptosis
in 54% of MCF-7 cells and necrosis in 20% of them, values higher than those observed in the
treatment of OFLOX at the same concentration. The results demonstrate an antitumor potential
of HPβCD/OFLOX. Larger studies are needed to evaluate the potential of HPβCD/OFLOX as
a future candidate in the treatment of breast cancer.
Description
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

